All trials | YES trials | MAYBE trials | NO trials | p value (YES vs. MAYBE vs. NO) | p value (YES+ MAYBE vs. NO) | p value (MAYBE + NO vs. YES) | |
---|---|---|---|---|---|---|---|
n = 194 | n = 41 | n = 14 | n = 139 | ||||
Byline author from the product manufacturer? | 76 (39) | 35 (85) | 10 (71) | 31 (22) | <.001 | <.001 | <.001 |
Median (LQ, UQ) proportion of byline authors from product manufacturer | 0 (0, 16) | 22 (9, 38) | 19 (0, 28) | 0 (0, 0) | <.001a | <.001b | <.001b |
Byline author reporting a financial conflict of interest with the product manufacturer?c | 126 (65) | 39 (95) | 14 (100) | 73 (53) | <.001 | <.001 | <.001 |
Median (LQ, UQ) proportion of byline authors reporting COI with product manufacturerc | 24 (0, 67) | 82 (59, 100) | 64 (49, 85) | 6 (0, 40) | <.001a | <.001b | <.001b |
Group name on the byline | 111 (57) | 25 (61) | 9 (64) | 77 (55) | .701 | .415 | .584 |
Is writing or editorial assistance in preparing the manuscript acknowledged? | .001 | <.001 | .002 | ||||
Acknowledgements or main text | 75 (39) | 25 (61) | 9 (64) | 41 (30) | |||
Professional writer is a byline author | 2 (1) | 1 (2) | 0 (0) | 1 (1) | |||
No assistance is acknowledged | 117 (60) | 15 (37) | 5 (36) | 97 (70) | |||
Study explicitly funded by product manufacturer? | 106 (55) | 41 (100) | 14 (100) | 51 (37) | <.001 | <.001 | <.001 |
Manufacturer involved in the design of the study? | <.001 | <.001 | <.001 | ||||
Yes | 71 (37) | 34 (83) | 10 (71) | 27 (19) | |||
No | 96 (50) | 4 (10) | 2 (14) | 90 (65) | |||
Not explicitly described | 27 (14) | 3 (7) | 2 (14) | 22 (16) | |||
Manufacturer involved in the data analysis? | <.001 | <.001 | <.001 | ||||
Yes | 66 (34) | 35 (85) | 10 (71) | 21 (15) | |||
No | 106 (55) | 4 (10) | 3 (21) | 99 (71) | |||
Not explicitly described | 22 (11) | 2 (5) | 1 (7) | 19 (14) | |||
Manufacturer involved in the reporting of the study? | <.001 | <.001 | <.001 | ||||
Yes | 64 (33) | 33 (81) | 10 (71) | 21 (15) | |||
No | 98 (51) | 3 (7) | 1 (7) | 94 (68) | |||
Not explicitly described | 32 (17) | 5 (12) | 3 (21) | 24 (17) | |||
Manufacturer control over the design of the study? | <.001 | <.001 | <.001 | ||||
Yes | 24 (12) | 14 (34) | 3 (21) | 7 (5) | |||
No | 108 (56) | 9 (22) | 3 (21) | 96 (69) | |||
Not explicitly described | 62 (32) | 18 (44) | 8 (57) | 36 (26) | |||
Manufacturer had control over the data analysis? | <.001 | <.001 | <.001 | ||||
Yes | 39 (20) | 23 (56) | 5 (36) | 11 (8) | |||
No | 111 (57) | 7 (17) | 4 (29) | 100 (72) | |||
Not explicitly described | 44 (23) | 11 (27) | 5 (36) | 28 (20) | |||
Manufacturer control over reporting of the study? | <.001 | <.001 | <.001 | ||||
Yes | 20 (10) | 9 (22) | 2 (14) | 9 (7) | |||
No | 111 (57) | 11 (27) | 4 (29) | 96 (69) | |||
Not explicitly described | 63 (33) | 21 (51) | 8 (57) | 34 (25) |